Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Terbinafine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.85 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.57 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.85 |
| ▸ | LMNA | P02545 | 3/20 | 0.85 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.85 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.85 |
| ▸ | SQLE | Q14534 | 2/20 | 0.85 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.57 |
| ▸ | HTR2A | P28223 | 2/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | CNR1 | P21554 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
| ▸ | EBP | Q15125 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terbinafine SCHEMBL1178093 | 0.99 | CYP2D6 (0.87) | CYP2D6LMNASLC6A2SIGMAR1ADRA2A | |
| Terbinafine SCHEMBL2793602 | 0.99 | CYP2D6 (0.87) | CYP2D6LMNASLC6A2SIGMAR1ADRA2A | |
| Terbinafine SCHEMBL26105446 | 0.93 | CYP2D6 (0.83) | CYP2D6LMNASLC6A2SIGMAR1ADRA2A | |
| Terbinafine SCHEMBL1650074 | 0.92 | CYP2D6 (0.95) | CYP2D6LMNASLC6A2SIGMAR1ADRA2A | |
| Terbinafine SCHEMBL5279646 | 0.92 | CYP2D6 (1.00) | CYP2D6LMNASLC6A2SIGMAR1ADRA2A | |
| Terbinafine SCHEMBL2028187 | 0.92 | CYP2D6 (1.00) | CYP2D6LMNASLC6A2SIGMAR1ADRA2A | |
| Terbinafine SCHEMBL2042785 | 0.92 | CYP2D6 (1.00) | CYP2D6LMNASLC6A2SIGMAR1ADRA2A | |
| Terbinafine SCHEMBL31374681 | 0.92 | CYP2D6 (1.00) | CYP2D6LMNASLC6A2SIGMAR1ADRA2A | |
| Terbinafine SCHEMBL29627458 | 0.92 | CYP2D6 (1.00) | CYP2D6LMNASLC6A2SIGMAR1ADRA2A | |
| Terbinafine SCHEMBL36794 | 0.92 | CYP2D6 (1.00) | CYP2D6LMNASLC6A2SIGMAR1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168233-A1 | TERBINAFINE FORMULATION | POWER PAPER LTD (IL) | 2010-07-01 | — | — | US | disclosed |
| EP-2120870-A2 | TERBINAFINE FORMULATION FOR IONTOPHORESIS | Power Paper Ltd. (IL) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008102349-A2 | TERBINAFINE FORMULATION FOR IONTOPHORESIS | POWER PAPER LTD (IL) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168233-A1 | TERBINAFINE FORMULATION | SLC6A12, SLC6A1, SLC6A11 | ADRA2A 2478/4885ADRA2C 952/4885OPRK1 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.